1.41
+47.21%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tvardi Therapeutics
From its filings with the US Securities and Exchange Commission
Tvardi Therapeutics is based in Sugar Land, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TVRD. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported revenue of $7.1m.
We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need. Based upon our founders’ seminal work and deep understanding of the transcription factor STAT3, we have designed an innovative approach to directly inhibit STAT3, a highly validated, yet historically undruggable target. Leveraging this expertise, we are developing a pipeline of STAT3 inhibitors with a differentiated mechanism of action and convenient oral dosing.
Our pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is our first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance our ability to target STAT3. We have been developing TTI-109 for several years, based on our recognition that retaining the full STAT3 inhibition mechanism of TTI-101 while enhancing delivery would broaden the potential utility of our platform across inflammatory and proliferative indications. We filed an Investigational New Drug (IND) application for TTI-109 in June 2025 and, following FDA acceptance, initiated a Phase 1 trial in healthy volunteers evaluating safety, tolerability, pharmacokinetics, and bioequivalence to TTI-101.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 31 Jan 2014
- Employees
- 80
- Website
- caratherapeutics.com ↗
- Head office
- 3 SUGAR CREEK CTR. BLVD., SUGAR LAND, TX, 77478
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Sujal ShahIndependent Chairman of the Board
- Dr. Imran AlibhaiChief Executive Officer, Director, since 2025
- Mr. Dan ConnChief Financial Officer
- Dr. Jeffrey LarsonSenior Vice President - Research & Development
- Mr. Stephen O'BrienVice President - Finance, Corporate Controller
- Dr. Yixin ChenVice President - Chemistry, Manufacturing and Controls
- Dr. John KauhChief Medical Officer
- Mr. Wallace HallIndependent Director
- Dr. Susan ShiffIndependent Director$262,500
- Ms. Cynthia SmithIndependent Director
- Mr. Michael WyzgaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 53
- Social
- 99
- Governance
- 16
- Women in the workforce
- 60%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CARA Therapeutics focuses on kappa opioid receptors for pain and pruritus treatments.
- The company has a pipeline including IV CR845 for acute pain and uremic pruritus.
- CARA Therapeutics employs 80 full-time employees in Stamford, Connecticut.
Weaknesses
- The company is a clinical-stage biopharmaceutical firm with no commercialized products yet.
- CARA Therapeutics has limited financial resources as a small biotech company.
- The firm's IPO in 2014 has not yet led to significant commercial revenue.
Opportunities
- CR845 shows anti-pruritic potency in preclinical models for uremic pruritus treatment.
- The company can expand its pipeline with CR701 for neuropathic and inflammatory pain.
- CARA Therapeutics can leverage its focus on peripheral nervous system therapeutics.
Threats
- The pharmaceutical industry faces intense competition for pain management solutions.
- Regulatory hurdles may delay approval of CR845 and CR701 product candidates.
- Clinical trial failures could impact the company's development pipeline significantly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.